We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Urinary VEGFA and Renal Pathology Evaluated for IgA Nephropathy Patients

By LabMedica International staff writers
Posted on 25 Sep 2021
Print article
The SpectraMax Plus 384 Microplate Reader can run both standard spectrophotometer and microplate reader applications on the same instrument (Photo courtesy of Molecular Devices)
The SpectraMax Plus 384 Microplate Reader can run both standard spectrophotometer and microplate reader applications on the same instrument (Photo courtesy of Molecular Devices)
Immunoglobulin A (IgA) nephropathy (IgAN) is the most common primary glomerulonephritis and is the leading cause of end-stage renal disease (ESRD) in China. Renal biopsy remains the golden standard for diagnosing and monitoring IgA nephropathy (IgAN).

Vascular endothelial growth factor-A (VEGFA) is an essential angiogenic cytokine and found to be crucial for the survival, differentiation and structure maintaining of these glomerular cells. VEGFA is therefore, pivotal for maintaining the glomerular filtration barrier function. The relationship of urinary and renal VEGFA in IgAN patients are still not clear.

Nephrologists at the Sun Yat-sen University (Guangzhou, China) recruited a total of 85 IgAN patients and 71 healthy controls without microscopic hematuria, proteinuria, hepatic disease and with normal serum creatinine. Samples of IgAN patients were obtained at the day of renal biopsy. Serum and morning urine collected from each subject were transferred to a separate vial after centrifuge and stored at −80 ℃ until assayed.

Serum levels of VEGFA were measured by ELH-VEGF-1 ELISA (RayBiotech, Peachtree Corners, GA, USA), and urine VEGFA levels were measured by ELISA from R&D Systems (Minneapolis, MN, USA). Absorbance was measured at 450 nm using the SpectraMax Plus 384 Microplate reader (Molecular Devices, San Jose, CA, USA). Renal biopsies of 27 IgAN patients were randomly selected from enrolled 85 IgAN patients and used for VEGFA testing by immunohistochemistry analysis. The expression levels of VEGFA and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were quantified by real-time PCR using Taqman with a fluorescence detection monitor 7900 Real-time PCR system (Applied Biosystems, Waltham, MA, USA).

The investigators reported that compared with healthy controls, urinary VEGFA level was elevated in IgAN patients (76.19 ± 63.67 pg/mg Cr versus 146.67 ± 232.71 pg/mg Cr), and not correlated with serum VEGFA level. Baseline urinary VEGFA was significantly associated with gender and tubular atrophy/interstitial fibrosis by stepwise multivariate regression analysis. Urinary VEGFA was higher in male patients accompanied with higher serum creatinine, larger proportion of hypertension and recurrent hematuria than in female patients. In the kidney of IgAN patients, VEGFA were robustly expressed in the parietal epithelial cells, podocytes, mesangial cells and tubular epithelial cells. After a follow-up duration of 38.53 ± 27.14 months, IgAN patients with higher urinary VEGFA level were found to have a poorer renal outcome of renal replacement therapy.

The authors concluded that increased urinary VEGFA might reflect certain renal pathology and, although not fully specific, still could be served as a valuable noninvasive indicator in predicting renal progression of IgAN. The study was published on September 8, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:

Sun Yat-sen University 
RayBiotech
R&D Systems 
Molecular Devices
Applied Biosystems

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The BIOFIRE® SPOTFIRE® R/ST Panel has received dual 510(k) clearance and CLIA-waiver approval (Photo courtesy of bioMérieux)

Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms

The COVID-19 pandemic has demonstrated the need for healthcare professionals to have diagnostic tests available as close as possible to the patient, providing actionable results quickly.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.